Boekhandel Douwes Den Haag

Norway's Pharmaceutical Revolution

Pursuing and Accomplishing Innovation in Nyegaard & Co., 1945-1997

Knut Sogner

Norway's Pharmaceutical Revolution

Norway's Pharmaceutical Revolution

Pursuing and Accomplishing Innovation in Nyegaard & Co., 1945-1997

Norway's Pharmaceutical Revolution

 

This is the story of how Norwegian company Nyegaard & Co. achieved international success in pharmaceuticals with a breakthrough product facilitating X-ray pictures of the soft tissues of the body. It is a story of both of personal initiatives and great organizational transformations: the corporation as entrepreneur.


Nog te verschijnen

€ 91,00

Bezorgen: Zodra beschikbaar


Beschrijving Norway's Pharmaceutical Revolution

The pharmaceutical revolution that gathered pace in the 1930s delivered a plethora of almost magical new drugs such as penicillin, streptomycin, cortisone, and the birth control pill. This revolution grew from academic-business relationships in five countries: USA, Germany, Great Britain, Switzerland, and France. Many other countries tried and failed to replicate this success, yet a handful of Scandinavia companies made important breakthroughs in a narrow band of
specialities. This is the story of how one Norwegian company— Nyegaard & Co. —achieved international success from the 1970s onwards with a breakthrough product facilitating X-ray pictures of the soft tissues of the body. The company succeeded by harnessing research skills and creating scientific and
business alliances abroad, building its own momentum step by step: the corporation as entrepreneur. It thereby broke with the conventional way a national medical ecosystem facilitated the crucial scientific progress. This is a story both of personal initiatives and great organizational transformations in several stages. In the 1950s, Nyegaard & Co. was a small hierarchical home market-oriented generics company. By the end of the 1990s, it had developed into a fairly large and multinational
hierarchical company, preoccupied as much with shareholder value as scientific progress. It has also become a company that no longer had the same ability to innovate as before and therefore became merged into another one.


ISBN
9780192869005
Pagina's
240
Verschijnt
NUR
780
Druk
1
Uitvoering
Hardback
Taal
Engels
Uitgever
OUP Oxford

Economie en bedrijf